based adjuvants (*e.g.,* Alhydrogel, Rehydragel, aluminum phosphate, Algammulin, aluminum hydroxide); oil based adjuvants (Freund's adjuvant (FA), Specol, RIBI, TiterMax, Montanide ISA50 or Seppic MONTANIDE ISA 720; cytokines (*e.g.,* GM-CSF or Flt3-ligand); microspheres; nonionic block copolymer-based adjuvants; dimethyl dioctadecyl ammoniumbromide (DDA) based adjuvants AS-1, AS-2 (Smith Kline Beecham); Ribi Adjuvant system based adjuvants; QS21 (Aquila); saponin based adjuvants (crude saponin, the saponin Quil A); muramyl dipeptide (MDP) based adjuvants such as SAF (Syntex adjuvant in its microfluidized form (SAF-m)); dimethyl-dioctadecyl ammonium bromide (DDA); human complement based adjuvants *m. vaccae* and derivatives; immune stimulating complex (iscom) based adjuvants; inactivated toxins; and attenuated infectious agents (such as *M. tuberculosis*).

In the Claims:

Please amend claims 104 and 107-112 to read as follows:

104. (Amended) A polypeptide consisting of an immunogenic portion of native WT1, or a variant thereof that differs from the immunogenic portion due to substitutions at between 1 and 3 amino acid positions within the immunogenic portion, such that the ability of the variant to react with WT1-specific T-cell lines or clones is not substantially diminished, wherein the immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2.

107. (Amended) A composition comprising an immunogenic portion of native WT1, wherein the immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2, in combination with a pharmaceutically acceptable carrier or excipient.

108. (Amended) A composition comprising an immunogenic portion of native WT1, wherein the immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2, in combination with a non-specific immune response enhancer.

109. (Amended) A composition according to claim 108, wherein the immune response enhancer is an adjuvant.

110. (Amended) A composition comprising:

(a) a WT1 polypeptide consisting of an immunogenic portion of a native WT1 or a variant thereof that differs from the immunogenic portion due to substitutions at between 1 and 3 amino acid positions within the immunogenic portion, such that the ability of the variant to react with antigen-specific T cell lines or clones is not substantially diminished; and

(b) a non-specific immune response enhancer that preferentially enhances a T cell response in a patient;

wherein said immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2.

111. (Amended) A composition according to claim 110, wherein the immune response enhancer is selected from the group consisting of Montanide ISA50, Seppic Montanide ISA 720, a cytokine, a microsphere, dimethyl dioctadecyl ammoniumbromide (DDA) based adjuvants, AS-1, AS-2, Ribi Adjuvant system based adjuvant, QS21, saponin based adjuvants, Syntex adjuvant in its microfluidized form, MV, ddMV, immune stimulating complex (iscom) based adjuvants, and inactivated toxins.

D3 Cont'd

112. (Amended) The composition of claim 111, wherein said cytokine is selected from the group consisting of GM-CSF and Flt3-ligand.

REMARKS

Reconsideration of the above-identified application is respectfully requested. Claims 104 and 107-112 are presently under consideration in this case. These claims have been amended for purposes of clarity and to advance prosecution of this application. It is urged that support for the above amendments can be found throughout the specification as originally filed and that none of the amendments constitutes new matter. It should also be noted that the above amendments are not to be construed as acquiescence with regard to the Examiner's rejections and are made without prejudice to prosecution of any subject matter modified and/or removed in a related divisional, continuation and/or continuation-in-part application.